Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)

Description

To demonstrate that microwave ablation (MWA) of up to 3 hepatic metastases, each with a maximum diameter of ≤ 2.5 cm will result in a 2-year local progression free survival of at least 90%. This is a standard of care (SOC) study.

Conditions

Colorectal Liver Metastases

Study Overview

Study Details

Study overview

To demonstrate that microwave ablation (MWA) of up to 3 hepatic metastases, each with a maximum diameter of ≤ 2.5 cm will result in a 2-year local progression free survival of at least 90%. This is a standard of care (SOC) study.

Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective Trial for Microwave Ablation as a Local Cure

Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)

Condition
Colorectal Liver Metastases
Intervention / Treatment

-

Contacts and Locations

Miami

Miami Cancer Institute, Miami, Florida, United States, 33176

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10021

Houston

MD Anderson Cancer Center, Houston, Texas, United States, 77030

Milwaukee

Medical College of WI, Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patient must be at least 18 years old.
  • 2. Patient has signed a written informed consent for the MWA and participation in the study.
  • 3. Patient with pathologically confirmed CRC with hepatic metastases confirmed on imaging (e.g., CT or MRI).
  • 4. Patient has up to 3 hepatic metastases, each up to 2.5 cm in largest diameter.
  • 5. Patient may have up to 5 lesions in the lung (none larger than ≥ 2.0 cm) and/or any lymph node ≤2.0 cm in the largest diameter
  • 6. Ability to safely create an ablation zone (AZ) that completely covers the tumor with minimal margin of 5.0 mm. Subcapsular (any tumor within 10 mm from the liver capsule) or perivascular (any tumor within 10 mm from a vessel larger than 3 mm) lesions may be included. For these tumors, the calculation of the margin will not apply to the area abutting the capsule or the vessel.
  • 7. The target tumor(s) is/are visible by US and/or CT in a location where MWA is technically achievable and safe based on the proximity to adjacent structures. Protective maneuvers such as hydrodissection for organ mobilization are allowed and will be recorded.
  • 8. ECOG performance status of 0-1.
  • 9. Platelet count \>50,000/mm3 (correctable allowed) within 30 days prior to study treatment.
  • 1. Patient is unable to lie flat or has respiratory distress at rest.
  • 2. Patient has uncontrolled and uncorrectable coagulopathy or bleeding disorders.
  • 3. Patient has a history of an allergic reaction to intravenous iodine that cannot be pre-medicated or prevents performance of a CT with IV contrast.
  • 4. Patient has evidence of active systemic infection.
  • 5. Patient has a debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment or follow up.
  • 6. Patient is currently participating in other experimental studies that could affect the primary endpoint.
  • 7. Patient unable to receive general anesthesia or adequate analgesia and sedation.
  • 8. Tumor location less than 25 mm from hilum (see diagrams with illustration of central ducts).
  • 9. Patient is currently pregnant or intends to become pregnant

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Society of Interventional Oncology,

Constantinos Sofocleous, MD, PhD, FSIR, FCIRSE, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2027-12-10